Avital Samish-Bareket

Binyamina, HA, Israel

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications

Piclidenoson, an A3 adenosine receptor agonist, demonstrates clinical benefit in canine osteoarthritis: a pilot study.

Piclidenoson, an A3 adenosine receptor agonist, demonstrates clinical benefit in canine osteoarthritis: a pilot study.

Journal: Frontiers in veterinary science
Published: April 04, 2026

Primary care physicians' perspectives on managing mild-to-moderate COVID-19 in populations at risk for progression to severe disease: a survey-based study.

Primary care physicians' perspectives on managing mild-to-moderate COVID-19 in populations at risk for progression to severe disease: a survey-based study.

Journal: BMC primary care
Published: November 30, 2025

Challenges in Interpreting Survival Metrics in Clinical Trials: The Utility of Restricted Mean Survival Analyses.

Challenges in Interpreting Survival Metrics in Clinical Trials: The Utility of Restricted Mean Survival Analyses.

Journal: International journal of radiation oncology, biology, physics
Published: January 30, 2025

Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring.

Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring.

Journal: JAMA network open
Published: January 22, 2025

The anti-obesity effect of namodenoson, an A3 adenosine receptor agonist.

The anti-obesity effect of namodenoson, an A3 adenosine receptor agonist.

Journal: International journal of obesity (2005)
Published: September 02, 2024

ER + HER2- early-stage breast cancer: association of HER2 expression, tumor characteristics, and outcomes.

ER + HER2- early-stage breast cancer: association of HER2 expression, tumor characteristics, and outcomes.

Journal: Breast cancer research and treatment
Published: June 11, 2024

Selecting postoperative adjuvant systemic therapy for early-stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays.

Selecting postoperative adjuvant systemic therapy for early-stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays.

Journal: Journal of surgical oncology
Published: April 30, 2024

Treatments and clinical outcomes in stage II colon cancer patients with 12-gene Oncotype DX Colon Recurrence Score® assay-guided therapy: real-world data.

Treatments and clinical outcomes in stage II colon cancer patients with 12-gene Oncotype DX Colon Recurrence Score® assay-guided therapy: real-world data.

Journal: ESMO open
Published: March 31, 2024

Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma.

Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma.

Journal: Biomedicines
Published: February 26, 2024

BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization.

BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization.

Journal: Breast cancer research and treatment
Published: October 18, 2023

Namodenoson Inhibits the Growth of Pancreatic Carcinoma via Deregulation of the Wnt/β-catenin, NF-κB, and RAS Signaling Pathways.

Namodenoson Inhibits the Growth of Pancreatic Carcinoma via Deregulation of the Wnt/β-catenin, NF-κB, and RAS Signaling Pathways.

Journal: Biomolecules
Published: September 28, 2023

Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT-1).

Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT-1).

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: July 30, 2023
Showing 1-12 of 28

Last Updated: 09/26/2026